Granulomatous Dermatitis Heralding Myelodisplastic/Myeloproliferative Neoplasms. Neoplastic or Reactive Cells? A Study of 2 Cases.
Journal
The American Journal of dermatopathology
ISSN: 1533-0311
Titre abrégé: Am J Dermatopathol
Pays: United States
ID NLM: 7911005
Informations de publication
Date de publication:
01 Jun 2022
01 Jun 2022
Historique:
pubmed:
17
2
2022
medline:
21
5
2022
entrez:
16
2
2022
Statut:
ppublish
Résumé
Skin manifestations in the context of underlying hematological malignancies are well known and not an infrequent clinical finding. They can represent specific neoplastic infiltrates or be considered as reactive. In the latter group, where granulomatous dermatitis is included, controversy has emerged recently. According to newly reported data, the histiocytes comprising these granulomata can carry the same molecular alterations found in the primary process. Moreover, the skin manifestations in these patients are sometimes the initial clue for the diagnosis of the underlying malignancy. We present here 2 cases with granulomatous skin infiltrates preceding the diagnosis of myelodysplastic/myeloproliferative neoplasms. In one of them, the same IDH2 mutation was detected in granulomatous lesions on the skin and in the bone marrow. This was performed by pyrosequencing instead of next-generation sequencing, with improved cost-effectiveness.
Identifiants
pubmed: 35170471
doi: 10.1097/DAD.0000000000002149
pii: 00000372-202206000-00012
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
456-460Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Li AW, Yin ES, Stahl M, et al. The skin as a window to the blood: cutaneous manifestations of myeloid malignancies. Blood Rev. 2017;31:370–388.
Alegría-Landa V, Rodríguez-Pinilla SM, Santos-Briz A, et al. Clinicopathologic, immunohistochemical, and molecular features of histiocytoid Sweet syndrome. JAMA Dermatol. 2017;153:651–659.
Federmann B, Bonzheim I, Yazdi AS, et al. Generalized palisaded neutrophilic and granulomatous dermatitis-a cutaneous manifestation of chronic myelomonocytic leukemia? A clinical, histopathological, and molecular study of 3 cases. Hum Pathol. 2017;64:198–206.
Vitte F, Fabiani B, Bénet C, et al. Specific skin lesions in chronic myelomonocytic leukemia: a spectrum of myelomonocytic and dendritic cell proliferations: a study of 42 cases. Am J Surg Pathol. 2012;36:1302–1316.
Vitale PA, Ackerman AB. Clues to diagnosis in dermatopathology. Vol II. Norris, MT: Raven Press; 1992.
Chu P, Connolly MK, LeBoit PE. The histopathologic spectrum of palisaded neutrophilic and granulomatous dermatitis in patients with collagen vascular disease. Arch Dermatol. 1994;130:1278–1283.
Rosenbach M, English JC III. Reactive granulomatous dermatitis: a review of palisaded neutrophilic and granulomatous dermatitis, interstitial granulomatous dermatitis, interstitial granulomatous drug reaction, and a proposed reclassification. Dermatol Clin. 2015;33:373–387.
Balin SJ, Wetter DA, Kurtin PJ, et al. Myelodysplastic syndrome presenting as generalized granulomatous dermatitis. Arch Dermatol. 2011;147:331–335.
Choi MJ, Shin D, Kim YC, et al. Interstitial granulomatous dermatitis with arthritis accompanied by anaplastic large cell lymphoma. J Dermatol. 2014;41:363–364.
Cornejo KM, Lum CA, Izumi AK. A cutaneous interstitial granulomatous dermatitis-like eruption arising in myelodysplasia with leukemic progression. Am J Dermatopathol. 2013;35:e26–e29.
Cases-Merida S, Lorente-Lavirgen A, Pérez-Gil A. Interstitial granulomatous dermatitis due to a rare myeloproliferative neoplasia. Indian J Dermatol. 2018;63:264–267.
Agis H, Weltermann A, Fonatsch C, et al. A comparative study on demographic, hematological, and cytogenetic findings and prognosis in acute myeloid leukemia with and without leukemia cutis. Ann Hematol. 2002;81:90–95.
Bénet C, Gomez A, Aguilar C, et al. Histologic and immunohistologic characterization of skin localization of myeloid disorders: a study of 173 cases. Am J Clin Pathol. 2011;135:278–290.
Swerdlow SHCE, Harris NL, Jaffe ES, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed. Lyon, France: IARC; 2017.
Meggendorfer M, Roller A, Haferlach T, et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood. 2012;120:3080–3088.
Gelsi-Boyer V, Trouplin V, Adélaïde J, et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol. 2009;145:788–800.
Itzykson R, Kosmider O, Renneville A, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol. 2013;31:2428–2436.
Yoneta K, Fujimoto N, Teramura K, et al. Disseminated granulomatous skin lesions associated with myelodysplastic syndrome treated successfully with tranilast: a case report and review of the literature. Eur J Dermatol. 2016;26:398–400.
Genovese G, Kähler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371:2477–2487.
Mason CC, Khorashad JS, Tantravahi SK, et al. Age-related mutations and chronic myelomonocytic leukemia. Leukemia. 2016;30:906–913.
Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015;126:9–16.